Pre-earnings options volume in Inhibrx (INBX) is normal with calls leading puts 4:1. Implied volatility suggests the market is anticipating a move near 7.3%, or $6.02, after results are released. Median move over the past eight quarters is 3.0%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBX:
- Is INBX a Buy, Before Earnings?
- Largest borrow rate increases among liquid names
- Inhibrx’s Promising Study on INBRX-106 for Advanced Head and Neck Cancer
- Inhibrx Biosciences Advances Cancer Treatment with INBRX-106 Study Update
- Inhibrx’s Phase 2 Study on INBRX-109: A Potential Breakthrough in Chondrosarcoma Treatment